KHIDI Korean Pavilion for ‘HIMSS Europe Digital Event’

HELSINKI, Sept. 3, 2020 /PRNewswire/ — Korea Health Industry Development Institute (KHIDI) is planning to participate in ‘HIMSS & Health 2.0 European Digital Event’ held for 5 days from September 7th to 11th, 2020 with competitive digital healthcare companies in Korea.

KHIDI is the government-affiliated institution which carries out the systematic and professional support for the improvement of public health and enhancement of the international competitiveness in the health industry. KHIDI has been specifically leading the development of the health industry such as medical services, pharmaceuticals, medical devices, foreign patient attraction, and digital healthcare industry.

In particular, in the HIMSS European event, the Korea Pavilion was operated by recruiting companies for three consecutive years following 2018 and 2019. Even for this upcoming event, eight competitive Korean companies will be participating online.

The enterprises with outstanding technology including Lemonhealthcare, F&D Partners, Mediage, Doai, Ikoob, U-Shin C&C, Insung information, QTT etc., will be showcasing their unique technologies such as medical device manufacturing, remote medical treatment system and medical software.

Deok-Cheol Kwon, the president of KHIDI stated that he hopes that Korea’s competitive companies and companies around the world will have a constructive forum for discussion on the promotion of human health and the development of the smart healthcare industry at HIMSS European digital event.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/khidi-korean-pavilion-for-himss-europe-digital-event-301122605.html

SOURCE Korea Health Industry Development Institute

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

17 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

17 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago